<?xml version="1.0" encoding="utf-8"?><rss version="2.0"><channel xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/"><title>RedState</title><link>https://redstate.com/erick/2010/07/30/does-the-washington-post-have-a-conflict-of-interest-in-its-editorials/feed/</link><description>Conservative News &amp; Politics</description><language>en-us</language><lastBuildDate>Fri, 12 Jun 2026 03:11:06 -0400</lastBuildDate><item><title>Does the Washington Post Have a Conflict of Interest in its Editorials?</title><description>&lt;![CDATA[If you are one of those people who believes there is no such thing as a coincidence, you&amp;#8217;ll have to ask if the Washington Post is pushing one of its editors&amp;#8217; spousal agendas.Reuters reported a while back that the Federal Trade Commission was considering ending &amp;#8220;pay for delay&amp;#8221; practices with generic drugs.Basically, when a generic drug manufacturer is ready to come on the scene with a generic, a name brand pharmaceutical company pays the generic to delay entry to the market.  Well, the  FTC cannot really stop it, but it has been urging Congress to do something about it.  One of the FTC Commissioners pushing an end to &amp;#8220;pay to delay&amp;#8221; is Jon Leibowitz, who acts as chairman.From Reuters:]]&gt;</description><pubDate>Fri, 30 Jul 2010 12:34:12 -0400</pubDate><creator xmlns="dc">&lt;![CDATA[Erick Erickson]]&gt;</creator><enclosure url="" type="image/jpeg" length="123" /><link>https://redstate.com/erick/2010/07/30/does-the-washington-post-have-a-conflict-of-interest-in-its-editorials-n35679</link></item></channel></rss>